A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Nelonemdaz in Patients With Acute Ischemic Stroke
Latest Information Update: 16 Dec 2024
At a glance
- Drugs Nelonemdaz (Primary)
- Indications Ischaemic stroke
- Focus Registrational; Therapeutic Use
- Acronyms RODIN
- Sponsors GNT Pharma
Most Recent Events
- 11 Dec 2024 According to a GNT Pharma media release, data from this study to be published in the 'JAMA' (Journal of the American Medical Association) Network Open.
- 11 Dec 2024 According to a GNT Pharma media release, results from this study were presented by Professor Jin Soo Lee at Ajou University Medical Center at the recent International Conference Stroke Update 2024 (ICSU 2024).
- 11 Dec 2024 Results presented in the GNT Pharma media release.